Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
VIVO's Cash to Debt is ranked higher than
98% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. VIVO: No Debt )
VIVO' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: No Debt

Equity to Asset 0.90
VIVO's Equity to Asset is ranked higher than
95% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. VIVO: 0.90 )
VIVO' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.92
Current: 0.9

0.35
0.92
Interest Coverage No Debt
VIVO's Interest Coverage is ranked higher than
87% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. VIVO: No Debt )
VIVO' s 10-Year Interest Coverage Range
Min: 4.78   Max: 9999.99
Current: No Debt

4.78
9999.99
F-Score: 7
Z-Score: 31.82
M-Score: -2.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 30.38
VIVO's Operating margin (%) is ranked higher than
97% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. VIVO: 30.38 )
VIVO' s 10-Year Operating margin (%) Range
Min: -22.13   Max: 32.9
Current: 30.38

-22.13
32.9
Net-margin (%) 20.16
VIVO's Net-margin (%) is ranked higher than
95% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. VIVO: 20.16 )
VIVO' s 10-Year Net-margin (%) Range
Min: -18.18   Max: 22.09
Current: 20.16

-18.18
22.09
ROE (%) 24.53
VIVO's ROE (%) is ranked higher than
97% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. VIVO: 24.53 )
VIVO' s 10-Year ROE (%) Range
Min: -44.78   Max: 27.89
Current: 24.53

-44.78
27.89
ROA (%) 21.52
VIVO's ROA (%) is ranked higher than
98% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. VIVO: 21.52 )
VIVO' s 10-Year ROA (%) Range
Min: -15.57   Max: 21.52
Current: 21.52

-15.57
21.52
ROC (Joel Greenblatt) (%) 77.25
VIVO's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. VIVO: 77.25 )
VIVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -34.55   Max: 82.47
Current: 77.25

-34.55
82.47
Revenue Growth (%) 8.90
VIVO's Revenue Growth (%) is ranked higher than
77% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. VIVO: 8.90 )
VIVO' s 10-Year Revenue Growth (%) Range
Min: 2.8   Max: 22.6
Current: 8.9

2.8
22.6
EBITDA Growth (%) 10.60
VIVO's EBITDA Growth (%) is ranked higher than
79% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. VIVO: 10.60 )
VIVO' s 10-Year EBITDA Growth (%) Range
Min: -2.3   Max: 22.5
Current: 10.6

-2.3
22.5
EPS Growth (%) 11.90
VIVO's EPS Growth (%) is ranked higher than
80% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. VIVO: 11.90 )
VIVO' s 10-Year EPS Growth (%) Range
Min: -27.9   Max: 35.7
Current: 11.9

-27.9
35.7
» VIVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

VIVO Guru Trades in Q1 2013

John Hussman 7,000 sh (New)
Jim Simons 61,200 sh (+70.59%)
John Keeley 54,470 sh (+27.95%)
Mario Gabelli 90,000 sh (+12.5%)
Joel Greenblatt 63,898 sh (+7.87%)
» More
Q2 2013

VIVO Guru Trades in Q2 2013

Chuck Royce 5,200 sh (New)
Paul Tudor Jones 9,800 sh (New)
John Hussman 12,500 sh (+78.57%)
Jim Simons 98,700 sh (+61.27%)
John Keeley 78,170 sh (+43.51%)
Joel Greenblatt 83,913 sh (+31.32%)
Mario Gabelli 90,000 sh (unchged)
» More
Q3 2013

VIVO Guru Trades in Q3 2013

Chuck Royce 19,600 sh (+276.92%)
Joel Greenblatt 155,306 sh (+85.08%)
Jim Simons 140,976 sh (+42.83%)
Paul Tudor Jones 12,600 sh (+28.57%)
John Keeley 87,470 sh (+11.9%)
Mario Gabelli 90,000 sh (unchged)
John Hussman 12,500 sh (unchged)
» More
Q4 2013

VIVO Guru Trades in Q4 2013

Jim Simons 237,495 sh (+68.46%)
John Keeley 92,870 sh (+6.17%)
Mario Gabelli 90,000 sh (unchged)
Chuck Royce 18,200 sh (-7.14%)
John Hussman 10,000 sh (-20%)
Joel Greenblatt 114,807 sh (-26.08%)
Paul Tudor Jones 7,600 sh (-39.68%)
» More
» Details

Insider Trades

Latest Guru Trades with VIVO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Reduce -26.08%0.03%$22.75 - $26.6 $ 21.82-11%114807
Joel Greenblatt 2013-09-30 Add 85.08%0.06%$21.93 - $24.86 $ 21.82-7%155306
Joel Greenblatt 2013-06-30 Add 31.32%0.02%$19.52 - $22.6 $ 21.821%83913
John Keeley 2013-06-30 Add 43.51%0.01%$19.52 - $22.6 $ 21.821%78170
John Hussman 2013-06-30 Add 78.57%0.01%$19.52 - $22.6 $ 21.821%12500
John Keeley 2013-03-31 Add 27.95%0.01%$20.25 - $22.815 $ 21.822%54470
John Hussman 2013-03-31 New Buy0.01%$20.25 - $22.815 $ 21.822%7000
Mario Gabelli 2012-12-31 Add 23.08%$18.75 - $20.6 $ 21.8210%80000
Joel Greenblatt 2012-09-30 Add 237%0.05%$16.3 - $20.61 $ 21.8218%55811
John Keeley 2012-09-30 Add 36.96%$16.3 - $20.61 $ 21.8218%41470
Mario Gabelli 2012-09-30 Add 62.5%$16.3 - $20.61 $ 21.8218%65000
Joel Greenblatt 2012-06-30 New Buy0.03%$18.27 - $20.83 $ 21.8213%16561
John Keeley 2012-03-31 Add 31.88%$17.29 - $20.12 $ 21.8226%27880
Mario Gabelli 2012-03-31 New Buy$17.29 - $20.12 $ 21.8226%35000
John Keeley 2011-03-31 Add 61.12%$20.74 - $23.78 $ 21.82-2%17240
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.10
VIVO's P/E(ttm) is ranked higher than
64% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.50 vs. VIVO: 25.10 )
VIVO' s 10-Year P/E(ttm) Range
Min: 18.94   Max: 48.85
Current: 25.1

18.94
48.85
P/B 5.80
VIVO's P/B is ranked lower than
61% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. VIVO: 5.80 )
VIVO' s 10-Year P/B Range
Min: 4.68   Max: 11.7
Current: 5.8

4.68
11.7
P/S 4.90
VIVO's P/S is ranked lower than
54% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. VIVO: 4.90 )
VIVO' s 10-Year P/S Range
Min: 2.06   Max: 10.95
Current: 4.9

2.06
10.95
PFCF 28.10
VIVO's PFCF is ranked lower than
59% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.36 vs. VIVO: 28.10 )
VIVO' s 10-Year PFCF Range
Min: 11.08   Max: 69.92
Current: 28.1

11.08
69.92
EV-to-EBIT 15.90
VIVO's EV-to-EBIT is ranked higher than
69% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. VIVO: 15.90 )
VIVO' s 10-Year EV-to-EBIT Range
Min: 12.5   Max: 37.1
Current: 15.9

12.5
37.1
PEG 5.30
VIVO's PEG is ranked lower than
60% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. VIVO: 5.30 )
VIVO' s 10-Year PEG Range
Min: 0.98   Max: 37
Current: 5.3

0.98
37
Shiller P/E 27.10
VIVO's Shiller P/E is ranked higher than
75% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. VIVO: 27.10 )
VIVO' s 10-Year Shiller P/E Range
Min: 22.17   Max: 105.81
Current: 27.1

22.17
105.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.50
VIVO's Dividend Yield is ranked higher than
94% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.28 vs. VIVO: 3.50 )
VIVO' s 10-Year Dividend Yield Range
Min: 1.24   Max: 4.83
Current: 3.5

1.24
4.83
Dividend Payout 0.65
VIVO's Dividend Payout is ranked lower than
60% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.27 vs. VIVO: 0.65 )
VIVO' s 10-Year Dividend Payout Range
Min: 0.27   Max: 5.8
Current: 0.65

0.27
5.8
Dividend growth (3y) 0.90
VIVO's Dividend growth (3y) is ranked higher than
59% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 45.30 vs. VIVO: 0.90 )
VIVO' s 10-Year Dividend growth (3y) Range
Min: 0.9   Max: 37.5
Current: 0.9

0.9
37.5
Yield on cost (5-Year) 4.16
VIVO's Yield on cost (5-Year) is ranked higher than
89% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. VIVO: 4.16 )
VIVO' s 10-Year Yield on cost (5-Year) Range
Min: 1.47   Max: 5.74
Current: 4.16

1.47
5.74
Share Buyback Rate -0.60
VIVO's Share Buyback Rate is ranked higher than
85% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.60 vs. VIVO: -0.60 )
VIVO' s 10-Year Share Buyback Rate Range
Min: 0.3   Max: -6.1
Current: -0.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 34.60
VIVO's Price/Net Cash is ranked lower than
83% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. VIVO: 34.60 )
VIVO' s 10-Year Price/Net Cash Range
Min: 14.91   Max: 172.21
Current: 34.6

14.91
172.21
Price/Net Current Asset Value 14.60
VIVO's Price/Net Current Asset Value is ranked lower than
66% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. VIVO: 14.60 )
VIVO' s 10-Year Price/Net Current Asset Value Range
Min: 9.39   Max: 97.23
Current: 14.6

9.39
97.23
Price/Tangible Book 7.30
VIVO's Price/Tangible Book is ranked lower than
65% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. VIVO: 7.30 )
VIVO' s 10-Year Price/Tangible Book Range
Min: 3.58   Max: 18.25
Current: 7.3

3.58
18.25
Price/DCF (Projected) 2.20
VIVO's Price/DCF (Projected) is ranked lower than
51% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. VIVO: 2.20 )
VIVO' s 10-Year Price/DCF (Projected) Range
Min: 1.01   Max: 4.18
Current: 2.2

1.01
4.18
Price/Median PS Value 0.90
VIVO's Price/Median PS Value is ranked higher than
74% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. VIVO: 0.90 )
VIVO' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 1.94
Current: 0.9

0.12
1.94
Price/Graham Number 2.80
VIVO's Price/Graham Number is ranked lower than
57% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. VIVO: 2.80 )
VIVO' s 10-Year Price/Graham Number Range
Min: 1.99   Max: 5.67
Current: 2.8

1.99
5.67
Earnings Yield (Greenblatt) 6.30
VIVO's Earnings Yield (Greenblatt) is ranked higher than
70% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. VIVO: 6.30 )
VIVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.7   Max: 8
Current: 6.3

2.7
8
Forward Rate of Return (Yacktman) 6.89
VIVO's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. VIVO: 6.89 )
VIVO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.8   Max: 2551.8
Current: 6.89

0.8
2551.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:MR4.Germany
Meridian Bioscience Inc. was incorporated in Ohio in 1976. It is a fully-integrated life science Company whose businesses in the development, manufacture, sale and distribution of diagnostic test kits, mainly for certain respiratory, gastrointestinal, viral and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers; and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company's operating segments are US Diagnostics, European Diagnostics, and Life Science. The Company's U.S. Diagnostics operating segment's business focuses on the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal, viral, respiratory and parasitic infectious diseases. Its European Diagnostics operating segment's business focuses on the sale and distribution of diagnostic test kits, manufactured both by the Company's U.S. Diagnostics operating segment and by third-party vendors. Life Science operating segment's business focuses on the development, manufacture, sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic companies, as well as contract development and manufacturing services under clinical cGMP conditions. The company's competitors are Abbott Laboratories Inc., Becton, Dickinson and Company, Thermo Fisher and Siemens, Quidel Corporation and Inverness Medical Innovations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide